Biofidelity announces the commercial launch of ASPYRE-Lung in the US

Biofidelity, a revolutionary genomic technology company dedicated to bringing the benefits of precision medicine to patients around the world, today announced the commercial launch of ASPYRE®-Lung in the US.

Scroll to Top